OPTIMIZE — Low-dose Tac+EVR not superior to Tac+MMF in KTRs ≥65 (2026) — Trial Summary

OPTIMIZE — Low-dose Tac+EVR not superior to Tac+MMF in KTRs ≥65 (2026): Randomized clinical trial (OPTIMIZE) in de novo kidney transplant recipients age ≥65 years comparing low-dose tacrolimus + everolimus + prednisolone (TEP) versus standard-dose tacrolimus + mycophenolate mofetil + prednisolone (T

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.